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Abstract 
Oral administration of camptothecin (CPT) derivatives and other 
antitumoral agents is being actively developed in order to improve the 
quality of life of patients with cancer. Though several lipophilic derivatives 
of CPT have shown interesting oral bioavailability in preclinical and 
clinical studies, only Topotecan has been approved for this route of 
administration.  Semisynthesis, antitumor activity, biological inhibition 
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mechanism, and in situ intestinal permeability of 9, 10-[1, 3]-
Dioxinocamptothecin (CDiox), an unexplored CPT derivative, have been 
studied in this paper. The hexacyclic analog was as effective as Topotecan 
and CPT in different tumor cell lines, showing an expected similar 
apoptosis cell mechanism and high ability to inhibit DNA synthesis in 
HeLa, Caco-2, A375 and MDA-MB-231 cell lines. Furthermore, in vitro 
and in situ pharmacokinetics transport values obtained for CDiox displayed 
more favourable absorption profile than CPT and Topotecan. 
Keywords: dioxinocamptothecin, antitumor, camptothecin, oral, 
permeability, transport 
Highlights:  
a) Synthesis, citotoxicity and intestinal permeability of  DioxinoCPT 
analog is presented 
 b) Permeability value of hexacyclic derivative was 5-fold higher than 
Topotecan  
c) Permeability value of the hexacyclic derivative was slightly higher than 
CPT  








Camptothecin (CPT), a natural alkaloid isolated from Camptotheca 
acuminata, was first reported by Wall et al. to have a potent antitumor 
activity against a broad spectrum of tumors [1, 2]. As soon as the 
identification of the enzyme Topoisomerase I (TopoI) as the major cellular 
target of CPT was confirmed (with the discovery of overexpressed levels of 
TopoI in tumor cells relative to normal cells), the elucidation of the 
structure-activity relationship of the alkaloid and the molecular mechanism 
of inhibition were priority in many investigations in the area of medicinal 
chemistry [3]. 
It is well established that successful inhibition of TopoI requires an 
unmodified lactone E ring moiety in the structure, however, the pH-
dependent reversible equilibrium of the α-hydroxy-δ-lactone ring is shifted 
toward the carboxilate open-ring form at physiological pH or above [4]. 
CPTs are S-phase-specific drugs and the stabilization of the covalent 
TopoI-DNA complex by CPT is a required step in its antitumor activity. 
Because of that, prolonged or repetitive exposure of this kind of drugs is 
necessary to increase cell killing, since the S phase is a short phase of the 
cell cycle [5]. 
Several CPT derivatives have been developed to improve the lactone 
stability and to limit the uncontrolled toxic effects. Among them, Topotecan 
(Hycamtin®) [6] and Irinotecan (Camptosar®) [7] are the only two analogs 
approved for clinical practice. While Irinotecan is used exclusively by i.v. 
infusion, Topotecan is also administered by oral route for the treatment of 
relapsed small cell lung cancer (SCLC) in patients with a prior complete or 





Figure 1. Camptothecin, Dioxinocamptothecin (CDiox) and representative     
analogues 
 
Further studies focused on the nature of the CPT derivatives, argue that 
highly lipophilic analogues provide several pharmaceutical advantages 
relative to water-soluble such as lactone stability, lack of metabolic 
conversion, broad antitumor activity, oral bioavailability and optimized 
therapeutic efficiency [9, 10].  
According to previous modifications of CPT, additional ring combination 
in positions 10-11, 7-9 and 9-10 showed potent antitumor activity, probably 
due to the extended planarity exerted by an additional hexacyclic-fussed 
ring [11]. Oxazines, amidines, furan and dihydrofuran rings fussed on CPT 
structure have been extensively studied with exceptional in vitro results 
[12, 13, 14]. 9,10-[1,3]-Dioxocamptothecin (CDiox), which can be 
regarded as a close structural variant of  9,10-(ethylendioxy) CPT, has not 
been considered for any prior study in spite of being as active as CPT in 
enhancing topo I-mediated cleavage of the DNA duplex [15, 16]. In 
addition, no violations of Lipinski rules, adequate polar surface area and a 
lipophilic cLogP value, complete a favorable theoretical calculation 




On the basis of the lipophilic behavior of CDiox and the promising results 
published for other water-insoluble CPT derivatives [18], a preliminary 
study to establish the oral availability of this analogue is presented in this 
work. To elucidate permeability and transport mechanism, experiments 
were carried out using Caco-2 cells and in situ perfusion studies in rats. 
2. Results and Discussion 
2.1 Chemistry 
CDiox was prepared by straightforward condensation of 10-
hydroxycamptothecin with an excess of formaldehyde in neat triflic acid. 
Although the reaction is effective in solvents such as nitromethane, acetic 
acid and acetonitrile with catalytic amounts sulfuric acid or triflic acid at 
50ºC, optimal conditions were obtained by performing the synthesis in neat 
triflic acid from 0ºC to room temperature overnight. The derivative was 




C-NMR, elemental analysis and 
exact mass. In the best of our knowledge no synthesis has been previously 
reported for this drug 
2.2 Biological studies. 
2.2.1 Cytotoxicity 
The in vitro antitumor activity of CDiox was assayed by MTT method 
against five human cancer cell lines, including cervical cancer (HeLa), 
colon adenocarcinoma (Caco-2),  malignant melanoma (A375), T cell 
lymphoblast (Jurkat), and breast cancer hormone sensitive cell line (MDA-
MB-231). CPT as parent compound and Rubitecan and Topotecan as well 
known effective oral CPT derivatives were used as reference drugs. IC50 
(µM) values are expressed in Table 1. The results indicate than CDiox is as 
potent as standard compounds across all the cell lines, revealing that the 1, 
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3-dioxine ring fussed on the CPT structure retains the antiproliferative 
activity. Results indicate that CDiox and Rubitecan are slightly more active 
against HeLa and Caco-2 cells than CPT and Topotecan, while, unmodified 
CPT is more effective against MDA-MB-231.  
      HeLa
 
   Caco-2      A375
 




CPT 0.420±0.025 0.131±0.011 0.187±0.005 0.110±0.007 0.342±0.015 
Topotecan 0.380±0.011 0.119±0.008 0.162±0.012 0.127±0.009 0.473±0.023 
Rubitecan 0.343±0.012 0.112±0.005 0.138±0.014 0.128±0.008 0.479±0.013 
CDiox 0.345±0.013 0.104±0.004 0.186±0.007 0.124±0.010 0.476±0.018 
 
Table 1. In vitro antitumor activity of CDiox analog and reference 
compounds against five human tumor cell lines, were measured by the 
MTT assay after 24h of incubation  and expressed as IC50 (µM) 
 
2.2.2 Flow cytometry assay. Apoptosis induction 
Cell death mechanism was investigated using Annexin V-FITC/PI flow 
cytometry assay. Experiments allow analyzing whether CDiox, CPT, 
Rubitecan and Topotecan were able to induce apoptosis in Caco-2 cells at 
concentrations of 0.05µM and 0.5 µM after 24h of incubation. In order to 
determine if the apoptosis induced by the compounds is time dependent, 
assays were also carried out after 48 h of incubation. 
As shown in Table 2, all tested compounds induced cell death mainly 
through apoptosis. Interestingly, the exposition of cell cultures to increased 
concentrations of the compounds significantly increased the number of 
apoptotic cells (early+ late apoptosis), while no important changes in the 
number of necrotic cells are observed (especially after 48h of incubation). 
CDiox activity is similar or even better than the compounds used as 
reference suggesting a promising anticancer candidate. The ability of 
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compounds to induce cellular apoptosis was in agreement with the results 
of the MTT assay.  
Figure 2 shows an example of flow cytometry scheme for untreated cells 
and cells exposed to 0.05µM or 0.5 µM of CDiox for 48 h  
 












 Control cells 
 
96.67±1.02 0.72±0.03 2.20±0.77 0,41±0.02 
24h CDiox 0.05µM 61.56±1.32 11.8±1.11 24.72±3.56 1.92±0.02 
 CDiox 0.5 µM 47.78±1.47 8.16±0.67 42.88±3.43 1.18±0.03 
 CPT 0.05µM 83.26±4.21 15.22±1.83 1.40±0.03 0.12±0.01 
 CPT 0.5 µM 81.62±2.33 1.64±0.04 13.70±1.95 3.04±0.01 
 Topotecan 0.05µM 71.40±3.84 5.42±0.03 19.54±2.35 3.64±0.02 
 Topotecan 0.5 µM 53.08±1.53 4.40±0.02 33.98±1.72 8.54±0.04 
 Rubitecan 0.05µM 65.04±1.78 11.08±0.02 21.03±1.16 3.85±0.05 
 Rubitecan 0.5 µM 45.05±1.38 8.24±0.77 39.82±1.85 6.89±0.03 
48h CDiox 0.05µM 57.00±2.29 3.56±0.55 33.54±1.44 5.90±0.12 
 CDiox 0.5 µM 37.04±1.39 3.68±0.03 56.08±2.56 3.20±0.05 
 CPT 0.05µM 51.12±1.29 3.18±0.06 41.38±1.92 4.32±0.02 
 CPT 0.5 µM 36.98±4.56 4.10±0.06 56.16±2.81 2.76±0.02 
 Topotecan 0.05µM 45.20±1.25 2.36±0.01 48.06±1.73 2.36±0.01 
 Topotecan 0.5 µM 38.26±2.92 5.74±0.02 53.12±1.88 2.88±0.01 
 Rubitecan 0.05µM 49.24±1.15 2.90±0.02 42.9±1.88 4.96±0.01 
 Rubitecan 0.5 µM 38.74±2.67 3.76±0.02 53.44±1.94 4.06±0.03 
Table 2. Percentage of Caco-2 cells in each state after treatment with 




Figure 2. Representative flow cytometry scheme of apoptotic Caco-2 cells 
stained with annexin V–FITC and PI. a) Control untreated cells; b) cells 
treated with 0.05µM of CDiox for 48 h; c) cells treated with 0.5 µM of 
CDiox for 48 h. Q1 quadrant (necrotic cells). Q2 quadrant (late apoptotic 
cells). Q3 quadrant (normal cells). Q4 quadrant (early apoptotic cells). 
 
 
2.2.3 Measurement of DNA synthesis 
Since TopoI inhibition has been shown to be a feasible strategy to block 
cancer cell proliferation, the effect of the compounds on DNA synthesis 
was evaluated by measuring the incorporation of BrdU into the DNA of 
HeLa, A375, Caco-2 and MDA-MB-231 cancer cell lines. Results, 
summarized in Figure 3, showed that all CPT derivatives, including CDiox, 
exhibited high ability to inhibit DNA synthesis in HeLa, A375, Caco-2 and 
MDA-MB-231 cell lines. Reduction values of BrdU incorporation can be 
considered similar for CDiox and the reference compounds when compared 
the effect at 0.8 μM. At higher concentration (1.6 μM) the activity of 
reference drugs is higher, showing a concentration-dependent effect. These 
results indicate that CDiox is a potent analogue with similar activity to 
CPT, Topotecan and Rubitecan. Moreover, it is remarkable the strong 
inhibition of DNA synthesis observed for 1.6 μM of CDiox in HeLa and 
Caco-2 cell lines. 










Figure 3. DNA synthesis measured by the BrdU incorporation assay 
(Roche) after incubation of cancer cells with different amount of 
compounds CPT, CDiox, Topotecan, and Rubitecan. a) in A375 melanoma 
cells. b) in Caco-2 cells. c) in HeLa cells. d) in MDA-MB-231 cells. BrdU 
incorporation values are the mean from three separate experiments with 
triplicate samples. * p<0.05, statistically significant difference from control 
value 
2.2.4 Apoptosis pathway: evaluation of the role of p53 Pho-p53 
In order to obtain more insights about the apoptosis pathway, the 
expression of the pro-apoptotic p53 and its activated form pho-p53 (Ser15) 
proteins were analyzed in the tumor panel cells lines treated with CDiox, 
CPT, Topotecan and Rubitecan for 24 h. Figure 4 reflects the results 
obtained from the Western blot assay. The results were referred to a 
negative control (without treatment). Coomassie blue stained gel was used 
to show that equivalent amounts of proteins were charged in all SDS–















































































Results indicate that the four compounds were able to induce 
phosphorylation of p53 (at Ser15) in MDA-MB-231 cells (Figure 4). In 
A375 cell line, p53 was phosphorylated by Rubitecan, CDiox and 
Topotecan and only slightly by CPT (figure 4). Data showed that the 
apoptosis induce by CDiox compound associated with increased pho-p53 
levels is similar in magnitude to Rubitecan and Topotecan in MDA-MB-
231 and A375 cancer cells. This pathway mediates the activation of the 
apoptosis in MDA-MB-231 and A375 cells but not in Caco-2 and HeLa 
cells. 
 
Figure 4. The p53 tumor suppressor protein activation in HeLa, MDA-MB-
231, Caco-2 and A375 after different compound treatments.  Activation of 
p53 was monitored by measuring phosphorylated (Ser15). P53 is 
phosphorylated by ATM, ATR and DNA-PK after signaling of DNA 
damage responses in order to block cell cycle and activate apoptosis. 
 
In addition, all compounds induced p53-independent apoptosis in HeLa and 
Caco-2 cells. These data are in good agreement with the results obtained by 
cell cytometry. In this regard, Caco-2 cells have been shown to contain a 
GT transition at codon 204, resulting in a truncated protein form in the 
central domain. Thus, we did not found p53 signal in Caco-2 cells [19]. 
This is an interesting finding that suggests two different apoptotic-induced 
mechanisms by these compounds depending on the cell type studied. 
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2.2.5 In vitro permeability 
CPT, as parent compound, and Topotecan, as the only camptothecin 
derivative approved for oral administration, were selected to be compared 
with CDiox to measure in vitro permeability values using Caco-2 
monolayer in both apical to basal (Pab) and in basal to apical (Pba) 
directions at different concentrations. 
Results are presented in Figure 5. Pab represents the permeability value in 
the physiological sense (from intestinal lumen to plasma) and Pba 
represents the hypothetical value of the permeability from the plasma to the 
intestinal lumen. Pba and Pba/Pab ratio values have not physiological 
application but they are very useful parameters in order to elucidate the 
mechanistic aspects of transport of the compounds. 
Permeation assays indicate that there are two different patterns of transport 
across the Caco-2 monolayer: one for Topotecan and another for CPT and 
CDiox 
Regarding to Topotecan, permeability value (Pab) is extremely low despite 
its effectiveness in oral administration. Moreover, Pba/Pab ratio is clearly 
higher than one, which is in the common pattern of efflux substrates and it 
is in accordance with the results described in literature for this compound 
[20, 21]. Pab is higher when Topotecan concentration increases due to the 
saturation of the secretion transporter, while Pba values decrease with 
increasing concentrations.  
Nevertheless, CPT and CDiox showed a different behavior. Permeability 
values of CPT and CDiox decreased with increasing concentrations but in 
both directions (Pab and Pba). This fact could indicate the contribution of 
transporters in both directions [22]. From Figure 5 it is possible to observe 
that at higher concentration (10, 25 and 50 µM) permeability values of 
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CDiox are higher than CPT indicating a more effective absorption behavior 
for the hexacyclic derivative. 
 
Figure 5. Permeability values obtained from apical to basal (Pab) and from 
basal to apical (Pba) at different concentrations in Caco-2 cell line. Data 
correspond to values of three independent experiments 
 
It is well-known that the main limitation of Topotecan is that it is substrate 
of efflux transporters such as Pgp and BCRP [23, 24]. As consequence, the 
oral fraction absorbed of orally administered Topotecan is less than 45% 
and it has been observed high interindividual variability in plasma levels 
after oral administration. 
In order to evaluate if CDiox is substrate of energy dependent transporter 
permeability, assays were carried out in presence of Sodium azide (SAz) as 
metabolic inhibitor [25]. The presence of SAz leads to inhibition of the 
active carrier mediated processes by depletion of ATP resources in the cells.  
Results in presence of the metabolic inhibitor show that permeability 



























transport of CDiox is not mediated by an active transporter in these assay 
conditions. In conclusion, the permeability behavior of CDiox obtained 
from in vitro assays indicates that this compound is a good candidate to be 
administered by oral route 
 
 Peff (cm/s) in absence of SAz Peff (cm/s) in presence of SAz 
CDiox (Pab) 1.00 ·10
-5
± 8.45·10
-7 8.05 ·10-6± 5.02· 10-7 
CDiox (Pba) 9.84 ·10
-6
± 5.43·10
-7 9.73 ·10-6± 4.87· 10-7 
 
Table 3: Permeability values of CDiox at 50µM in presence and in absence 
of Sodium Azide (SAz) 
 
The determination of permeability parameter (Peff) in preclinical studies is 
a crucial step to determine the suitability of the candidates for oral 
administration in early stages.  Figure 6 and table 4 show the oral fraction 
absorbed data (Fa) predicted for CDiox and the reference compounds based 
on the permeability values obtained experimentally and on the previously 
validated Peff-Fa correlation. This correlation has been obtained with drugs 
in solution, thus it represents the maximum oral fraction absorbed 
achievable in absence of solubility or limited solution. 
 


















Figure 6. Oral fraction absorbed vs Permeability values through Caco-2 
monolayers obtained from apical to basal direction (Pab) at 50 µM 
concentration of the compounds assayed. Grey cross correspond on CDiox 
values, grey squares correspond on CPT derivative compounds. Diamonds 
data correspond to the internally validated correlation between Caco-2 
permeability and oral fraction absorbed (unpublished data). Grey triangles 
correspond to reference compounds of high (caffeine and metroprolol), 
intermediate (cimetidine) and low permeability (lucifer yellow). Data 
correspond to values of three independent experiments. 
 
A high oral fraction absorbed (higher than 50%) is necessary to be a 
potential oral drug candidate. Lower values would difficult the 
development of an oral product and lead to the selection of other extravasal 
(intramuscular) or intravenous route. Preliminary results indicate that 
CDiox is a good candidate for oral administration. Its permeability value at 
50 µM is 5-fold higher than Topotecan and slightly higher than CPT, 
showing no (or minimum) affinity for Pgp, which could be a favorable 































Caco-2 cells permeability (cm/s) 
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2.2.6 In situ permeability. Rat perfusion assay 
In situ outcomes, carried out using perfusion rat model, are in accordance 
with obtained from cell culture assays.  
Absorption rate constants, Ka, and Peff values, are higher for hexacyclic 
derivative than for CPT and Topotecan. In addition, CDiox displays much 
better absorption profile than a well known high oral permeability standard 
Metropolol. (Table 5 and Figure 7). 
 
Figure 7. CPT, Topotecan and CDiox absorption rate coefficients in rats. 
 
























Table 5.  Absorption rate coefficients, Ka, and permeability values obtained 
in situ in rat. Metoprolol is used as model compound of high oral 
























The hexacyclicCPT derivative, 9, 10-[1,3]-Dioxocamptothecin (CDiox) has 
been synthesized and evaluated in vitro for its antitumor activity and oral 
biodisponibility. CDiox showed citotoxicity comparable to other 
topoisomerase I inhibitors reference compounds as CPT, Topotecan and 
Rubitecan producing DNA synthesis inhibition and apoptosis induction. 
Transport studies, carried out using Caco-2 cell monolayers and in situ 
perfusion in rat, indicated that the permeability is clearly better than for 
Topotecan, thus ensuring a higher oral fraction absorbed. Moreover, 
mechanistic studies showed that CDiox is not a Pgp substrate, which is an 
important goal for an anticancer drug as it ensures less variable drug 
absorption and broad tissue distribution as well as much better penetration 
to cancer cells. CDiox showed a promising antitumor profile and 
improvement as an effective drug for oral administration 
4. Experimental protocols 
4.1 Chemistry 
4.1.1 Materials and instruments 
All reagents and solvents were reagent grade. 10-Hydroxycamptothecin 
was purchase by AKScientific. Formaline, triflic acid, H2SO4, and standard 
solvents were purchase from Sigma Aldrich. Column chromatography was 
carried out on silica gel (Merck 200-300 mesh). TLC analysis was 
elaborated on silica gel plates (Merck 60F254).
 1
H NMR and 
13
C NMR 
spectra were recorded in DMSO-d6 at 300MHz with a Bruker instrument. 
Mass spectra were recorded using an Acquity UPLC system (Waters Corp.) 
The separation was carried out on a C18 column (50 mm × 2.1 mm i.d., 
1.7μm). The analysis was achieved with gradient elution using methanol 
and water (containing 0.01% formic acid) as the mobile phase. The 
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injection volume was 2μL. The spectrometer was connected to the UPLC 
system via electrospray ionization (ESI) interface. The ESI source was 
operated in positive ionization mode with the capillary voltage at 3.0 kV 
4.1.2 Chemical synthesis 
To a neat mixture of solid 10-hydroxycamptothecin and formaldehyde 
solution (36%) was added drop wise triflic acid at 0ºC. After being stirred 
for 12h at room temperature, ice water was added and the precipitated was 
purified by column chromatography to give CDiox 
Silica gel chromatography (eluent: CH2Cl2/MeOH 95:5).Yellow powder. 
Yield: 95%. 
1
H-NMR (300 MHz; DMSO-d6) δ: 0.88 (t, 3H, -CH3, J=7.4 
Hz); 1.80-1.93 (m, 2H); 5.19 (s, 2H); 5.30 (s, 2H); 5.41 (s, 4H); 6.49 (s, 
1H, -OH); 7.27 (s, 1H); 7.43 (d, 1H, J=9.2Hz); 7.80 (d, 2H, J= 9.1Hz); 8.39 
(s, 1H).  
13
C NMR (300 MHz, DMSO-d6) δ- 7.76, 30.2, 50.35, 53.41, 
65.22, 72.37, 95.78, 118.08, 118.94, 122.55, 127.19, 128.96, 129.60, 
130.03, 143.53, 145.90, 148.88, 150.02, 153.71, 156.85, 172.51. HRMS 
(m/z): calcd. for C22H18N3O6 (M + Na): 429.1063, found: 429.1063.  Anal. 
Calcd. for C22H18N2O6 (429.10): C, 61.54; H, 4.23; N, 6.52. Found: C, 
61.54; H, 4.23; N, 6.52. 
4.2 Biological assays 
Cell culture conditions attached to Supp. Inf. 
4.2.1 Cytotoxic studies 
The in vitro antiproliferative activity was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay[26]. 
Cells were seeded in a total volume of 200 µL of culture medium in 96-
well microtiter plates with flat-bottomed wells at a density of 25000 cells 
per well. Cultures were incubated at 37 ºC in a 5% carbon dioxide 
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atmosphere. 24 h later, the medium was replaced with a fresh medium and 
compounds at increasing concentrations were added. Samples solutions 
were prepared in DMSO 0.1% or miliQ water in the case of Topotecan. 
Plates were incubated for 24, 48, or 72 h and then, 20 µL of MTT solution 
(5 mg/mL) were added to each well. The samples were incubated at 37ºC 
for 3 h to allow reaction for the formazan formation. Absorbance was 
measured at 570 nm with a Labsystems Multiskan EX plate reader and the 
values were corrected with reference to the measurement at 630 nm.  
4.2.2 Flow cytometry assay 
The nature of compounds effects on the cells was determined with the aid 
of flow cytometry, after the double staining with propidium iodide (PI) and 
annexin V–fluorescein isothiocyanate (annexinV) [27]. Cells were treated 
with CDiox or the references compounds (CPT, Topotecan and Rubitecan) 
at 0.05 or 0.5 µM and then were stained with annexinV and PI. AnnexinV 
has high affinity for the membrane phospholipid phosphatidylserine and, 
for this reason, is useful to identify apoptotic cells which exposed 
phosphatidylserine. PI is a standard staining compound that allows 
distinguishing viable from nonviable cells. Viable cells exclude PI, whereas 
the membranes of dead or damaged cells are permeable to PI. The double 
staining allows us to identify four groups of cells: a) cells that exclude both 
staining molecules are alive, b) cells that stain positive for annexinV and 
negative for PI are undergoing apoptosis, c) cells that stain positive for both 
annexinV and PI are in the end stage of apoptosis and d) cells that stain 
negative for annexinV and positive for PI undergoing necrosis or are 
already dead. 
The flow cytometry analyses were carried out by using a Beckman Coulter 
EPICS XL-MCL cytometer. Cells were stained using the annexin V–
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fluoresceinisothiocyanate apoptosis detection kit (Roche) that provides a 
double staining with PI and annexinV [27]. 
4.2.3 Measurement DNA synthesis 
Proliferation of cell lines was determined with the “Cell proliferation 
ELISA BrdU colorimetric assay” from Roche. Cells were cultured in 96 
wells plates at density of 25,000 cells/well. 24 h after seeding, the 
compounds were added to the corresponding wells. After 24 h of 
incubation the cell lines were fixed and the immunoassay was performed 
according the manufacturer’s protocol. The reaction was measured with the 
spectrophotometer Spectra MAXPLUS 384 from Molecular Devices, at 
wavelengths of 370-492 nm and 3 intervals of 5 min. Differences in 
absorbance values are proportional to the incorporation of BrdU. 
4.2.4 Total protein extraction 
Total protein extracts were extracted from approximately 10
6
 cells lysed in 
ice for 15 min using 100 µL of lysis buffer (20 mM Hepes, pH 7.4, 1% 
Triton X-100, 100 mM NaCl, 50 mM, NaF, 10 mM, β-glycerophosphate, 1 
mM activated sodium orthovanadate, 1 mM PMSF and 2 µL/mL protein 
proteases inhibitor cocktail). Then, the suspension was spun-down at 
13,000 xg for 10 min at 4 ºC, and supernatants were collected and stored at 
-80 ºC until their use. Protein content
 
was determined by a modified Lowry 
method [28]. 
 
4.2.5 Western blot analysis 
Western blotting is an important technique used for identifying specific 
proteins from a complex mixture of proteins obtained from cells. Aliquots 
of cell lysates (30 μg protein) were added to sample buffer containing 10% 
β-mercaptoethanol and the mixture was immediately boiled during 5 min. 
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Proteins were separated by electrophoresis in sodium dodecyl sulfate-
polyacrylamide (12%) gels (SDS-PAGE), at 100 V during 2 h. After that, 
the proteins were electroblotted (Bio-Rad) onto nitrocellulose membranes. 
Membranes were blocked with 0.05 g/ml non-fat milk or with 0.05 g/ml 
BSA in TBS containing 0.2% Tween 20 (TBST), depending on the 
antibody, washed three times at room temperature, and incubated for 2 h at 
room temperature with primary antibodies diluted in TBST with 0.01 g/ml 
non-fat milk as follows, hsp70 (1:1000, Stressgene), phopho-p53 (1:1000, 
Abcam), p53 (1:1000, Calbiochem), and bax (1:1000, GeneTex). As 
loading controls, antibodies that recognize α-tubulin or α-actin (1:1000, 
Santa Cruz BioTech. USA) antibodies were used. The blots were washed 
again with TBST and further incubated for 1 h with a secondary mouse, 
rabbit or goat antibody conjugated with horseradish peroxidase. Blots were 
incubated with ECL
TM
 Western Blotting Detection Reagents as indicated 
the manufacturer protocol (Amersham GE HealthcareBio-Sciences AB, 
Uppsala, Sweden). Chemioluminescent signals were assessed using a 
General Electric´s scanning densitometer (LAS-4000). 
 
4.3 Transport studies 
4.3.1 Cell monolayer cultures 
Cell monolayers were prepared by seeding 400,000 cells on each 
polycarbonate membrane placed in the base of transwell inserts 
(MILLICEL

-PCF, surface area 4.2 cm
2
, 0,4 µm pore size) [29, 30]. 
Cultures were grown in Dulbecco’s modified Eagle’s media, as described 
previously until confluence during 19-22 days maintaining the cultures at 
standard conditions of 37C under 90% humidity and 5% CO2 [31]. The 
integrity of each cell monolayer was tested by measuring its transepithelial 
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electrical resistance (TEER) value before and after each transport assay.  
Normal TEER values for Caco-2 monolayers were ranging 500-750 cm
2
 
[32]. Cell monolayers with TEER values less than 420 cm
2 
were 
discarded. Hank’s balanced salt solution (HBSS) (9.8 g/L) supplemented 
HEPES (5.96 g/L) was used for all the experiments after adjusting pH to 
the desired value.  
4.3.2 In vitro permeability determination 
The in vitro transport study was developed using the Caco-2 cell 
monolayers (ATCC) with an appropriate trans-epithelial electrical 
resistance (TEER) value.  
Tested compound solutions were loaded into the donor side and buffer was 
added to the receiver chamber of each well. The six-well plate containing 
the inserts with the cell monolayers was put into an orbital environmental 
shaker maintained at a constant temperature (37 C) and agitation rate (50 
rpm) during all the experiments.  To carry out transport assays in presence 
of SAz, it was always placed on both sides of the cell monolayer. Four 
samples of 200 µL each were collected at 15, 30, 60 and 90 minutes in the 
receiver chamber and the volume was replaced each time with fresh buffer. 
Moreover, two samples of 200 µL each were taken at the start and the end 
of the assay from the donor chamber.  
HPLC analysis and pharmacokinetics parameters are described in Supp. 
Inf. 
4.3.3 In situ assays: rat perfusion studies 
Male Wistar rats were weighted after two hours fast with access to water. 
Rats were anesthetized using a mixture of diazepam (Valium, Roche) (1.67 
mg/kg), ketamine (Ketolar; Parke-Davis) (50 mg/kg) and atropine (atropine 
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sulfate; Braun) (1 mg/kg) and placed on heated surface to be maintained at 
37˚C. 
The surgical procedure consists on a midline abdominal incision in order to 
create a compartment in the small intestine with the aid of two syringes and 
two three-way stopcock valves. The bile duct was closed before the 
perfusion to prevent enterohepatic recycling and the presence of bile salts 
in lumen. Studies employed the entire small intestine. The drug solution is 
placed in the intestinal segment with the aid of the syringes and samples of 
the intestinal fluid are withdrawn at predefined times to analyze the 
remaining drug concentration. Test solutions at 50 µM of the reference and 
test compounds were prepared freshly before each use. Sampling of the 
perfusate into glass tubes was carried out at fixed times, after 5 min at 
intervals of 5 min up to 30 min. 
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